ID   TGFR1_HUMAN             Reviewed;         503 AA.
AC   P36897;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   02-NOV-2010, entry version 130.
DE   RecName: Full=TGF-beta receptor type-1;
DE            Short=TGFR-1;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor-like kinase 5;
DE            Short=ALK-5;
DE   AltName: Full=Serine/threonine-protein kinase receptor R4;
DE            Short=SKR4;
DE   AltName: Full=TGF-beta type I receptor;
DE   AltName: Full=Transforming growth factor-beta receptor type I;
DE            Short=TGF-beta receptor type I;
DE            Short=TbetaR-I;
DE   Flags: Precursor;
GN   Name=TGFBR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=94061986; PubMed=8242743; DOI=10.1016/0092-8674(93)90489-D;
RA   Franzen P., ten Dijke P., Ichijo H., Yamashita H., Schulz P.,
RA   Heldin C.-H., Miyazono K.;
RT   "Cloning of a TGF beta type I receptor that forms a heteromeric
RT   complex with the TGF beta type II receptor.";
RL   Cell 75:681-692(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=98086485; PubMed=9417915; DOI=10.1006/geno.1997.5023;
RA   Vellucci V.F., Reiss M.;
RT   "Cloning and genomic organization of the human transforming growth
RT   factor-beta type I receptor gene.";
RL   Genomics 46:278-283(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Lynch M.A., Song H., DeGroff V.L., Alam K.Y., Adams E.M.,
RA   Weghorst C.M.;
RT   "The genomic structure of the gene encoding the human transforming
RT   growth factor beta type I receptor.";
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   FUNCTION, PHOSPHORYLATION AT THR-185; THR-186; SER-187; SER-189 AND
RP   SER-191, SUBCELLULAR LOCATION, SUBUNIT, AND MUTAGENESIS OF
RP   185-THR-THR-186; SER-187; SER-189; SER-191; THR-200 AND THR-204.
RX   PubMed=7774578;
RA   Wieser R., Wrana J.L., Massague J.;
RT   "GS domain mutations that constitutively activate T beta R-I, the
RT   downstream signaling component in the TGF-beta receptor complex.";
RL   EMBO J. 14:2199-2208(1995).
RN   [6]
RP   INTERACTION WITH CD109.
RX   PubMed=16754747; DOI=10.1096/fj.05-5229fje;
RA   Finnson K.W., Tam B.Y.Y., Liu K., Marcoux A., Lepage P., Roy S.,
RA   Bizet A.A., Philip A.;
RT   "Identification of CD109 as part of the TGF-beta receptor system in
RT   human keratinocytes.";
RL   FASEB J. 20:1525-1527(2006).
RN   [7]
RP   INTERACTION WITH RBPMS.
RX   PubMed=17099224; DOI=10.1093/nar/gkl914;
RA   Sun Y., Ding L., Zhang H., Han J., Yang X., Yan J., Zhu Y., Li J.,
RA   Song H., Ye Q.;
RT   "Potentiation of Smad-mediated transcriptional activation by the RNA-
RT   binding protein RBPMS.";
RL   Nucleic Acids Res. 34:6314-6326(2006).
RN   [8]
RP   INTERACTION WITH TRAF6.
RX   PubMed=18758450; DOI=10.1038/ncb1780;
RA   Sorrentino A., Thakur N., Grimsby S., Marcusson A., von Bulow V.,
RA   Schuster N., Zhang S., Heldin C.H., Landstrom M.;
RT   "The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a
RT   receptor kinase-independent manner.";
RL   Nat. Cell Biol. 10:1199-1207(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [10]
RP   3D-STRUCTURE MODELING OF 34-114.
RX   MEDLINE=96096781; PubMed=8521960; DOI=10.1016/0014-5793(95)01239-7;
RA   Jokiranta T.S., Tissari J., Teleman O., Meri S.;
RT   "Extracellular domain of type I receptor for transforming growth
RT   factor-beta: molecular modelling using protectin (CD59) as a
RT   template.";
RL   FEBS Lett. 376:31-36(1995).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 162-503 IN COMPLEX WITH
RP   FKBP1A.
RX   PubMed=10025408; DOI=10.1016/S0092-8674(00)80555-3;
RA   Huse M., Chen Y.-G., Massague J., Kuriyan J.;
RT   "Crystal structure of the cytoplasmic domain of the type I TGF beta
RT   receptor in complex with FKBP12.";
RL   Cell 96:425-436(1999).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 162-503, PHOSPHORYLATION, AND
RP   INTERACTION WITH SMAD2 AND FKBP1A.
RX   PubMed=11583628; DOI=10.1016/S1097-2765(01)00332-X;
RA   Huse M., Muir T.W., Xu L., Chen Y.-G., Kuriyan J., Massague J.;
RT   "The TGF beta receptor activation process: an inhibitor- to substrate-
RT   binding switch.";
RL   Mol. Cell 8:671-682(2001).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 175-500 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=15177479; DOI=10.1016/j.bmcl.2004.04.007;
RA   Sawyer J.S., Beight D.W., Britt K.S., Anderson B.D., Campbell R.M.,
RA   Goodson T. Jr., Herron D.K., Li H.-Y., McMillen W.T., Mort N.,
RA   Parsons S., Smith E.C.R., Wagner J.R., Yan L., Zhang F.,
RA   Yingling J.M.;
RT   "Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-
RT   dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming
RT   growth factor-beta type I receptor kinase domain.";
RL   Bioorg. Med. Chem. Lett. 14:3581-3584(2004).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 201-503 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=15317461; DOI=10.1021/jm0400247;
RA   Gellibert F., Woolven J., Fouchet M.-H., Mathews N., Goodland H.,
RA   Lovegrove V., Laroze A., Nguyen V.-L., Sautet S., Wang R., Janson C.,
RA   Smith W., Krysa G., Boullay V., De Gouville A.-C., Huet S.,
RA   Hartley D.;
RT   "Identification of 1,5-naphthyridine derivatives as a novel series of
RT   potent and selective TGF-beta type I receptor inhibitors.";
RL   J. Med. Chem. 47:4494-4506(2004).
RN   [15]
RP   VARIANT TGFBR1*6A ALA-24--26-ALA DEL, AND VARIANT TGFBR1*10A ALA-26
RP   INS.
RX   PubMed=9661882;
RA   Pasche B., Luo Y., Rao P.H., Nimer S.D., Dmitrovsky E., Caron P.,
RA   Luzzatto L., Offit K., Cordon-Cardo C., Renault B., Satagopan J.M.,
RA   Murty V.V.V.S., Massague J.;
RT   "Type I transforming growth factor beta receptor maps to 9q22 and
RT   exhibits a polymorphism and a rare variant within a polyalanine
RT   tract.";
RL   Cancer Res. 58:2727-2732(1998).
RN   [16]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN CANCER RISK.
RX   PubMed=12947057; DOI=10.1200/JCO.2003.11.524;
RA   Kaklamani V.G., Hou N., Bian Y., Reich J., Offit K., Michel L.S.,
RA   Rubinstein W.S., Rademaker A., Pasche B.;
RT   "TGFBR1*6A and cancer risk: a meta-analysis of seven case-control
RT   studies.";
RL   J. Clin. Oncol. 21:3236-3243(2003).
RN   [17]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN PROSTATE CANCER.
RX   PubMed=15385056; DOI=10.1186/1471-2156-5-28;
RA   Kaklamani V.G., Baddi L., Rosman D., Liu J., Ellis N., Oddoux C.,
RA   Ostrer H., Chen Y., Ahsan H., Offit K., Pasche B.;
RT   "No major association between TGFBR1*6A and prostate cancer.";
RL   BMC Genet. 5:28-28(2004).
RN   [18]
RP   VARIANTS LDS1A ILE-200; ARG-318; GLY-400 AND PRO-487.
RX   PubMed=15731757; DOI=10.1038/ng1511;
RA   Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T.,
RA   Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A.,
RA   Spevak P.J., Cameron D.E., De Backer J.F., Hellemans J., Chen Y.,
RA   Davis E.C., Webb C.L., Kress W., Coucke P.J., Rifkin D.B.,
RA   De Paepe A.M., Dietz H.C.;
RT   "A syndrome of altered cardiovascular, craniofacial, neurocognitive
RT   and skeletal development caused by mutations in TGFBR1 or TGFBR2.";
RL   Nat. Genet. 37:275-281(2005).
RN   [19]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN PROSTATE CANCER.
RX   PubMed=15505640; DOI=10.1038/sj.pcan.4500765;
RA   Suarez B.K., Pal P., Jin C.H., Kaushal R., Sun G., Jin L., Pasche B.,
RA   Deka R., Catalona W.J.;
RT   "TGFBR1(*)6A is not associated with prostate cancer in men of European
RT   ancestry.";
RL   Prostate Cancer Prostatic Dis. 8:50-53(2005).
RN   [20]
RP   VARIANT LDS1A LEU-241.
RX   PubMed=16596670; DOI=10.1002/ajmg.a.31202;
RA   Ades L.C., Sullivan K., Biggin A., Haan E.A., Brett M., Holman K.J.,
RA   Dixon J., Robertson S., Holmes A.D., Rogers J., Bennetts B.;
RT   "FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation
RT   disorders revisited.";
RL   Am. J. Med. Genet. A 140:1047-1058(2006).
RN   [21]
RP   VARIANT LDS1A LEU-241, VARIANT AAT5 GLN-487, AND VARIANT HIS-267.
RX   PubMed=16791849; DOI=10.1002/humu.20353;
RA   Matyas G., Arnold E., Carrel T., Baumgartner D., Boileau C.,
RA   Berger W., Steinmann B.;
RT   "Identification and in silico analyses of novel TGFBR1 and TGFBR2
RT   mutations in Marfan syndrome-related disorders.";
RL   Hum. Mutat. 27:760-769(2006).
RN   [22]
RP   VARIANTS LDS2A GLU-232; TRP-487; PRO-487 AND GLN-487.
RX   PubMed=16928994; DOI=10.1056/NEJMoa055695;
RA   Loeys B.L., Schwarze U., Holm T., Callewaert B.L., Thomas G.H.,
RA   Pannu H., De Backer J.F., Oswald G.L., Symoens S., Manouvrier S.,
RA   Roberts A.E., Faravelli F., Greco M.A., Pyeritz R.E., Milewicz D.M.,
RA   Coucke P.J., Cameron D.E., Braverman A.C., Byers P.H., De Paepe A.M.,
RA   Dietz H.C.;
RT   "Aneurysm syndromes caused by mutations in the TGF-beta receptor.";
RL   N. Engl. J. Med. 355:788-798(2006).
RN   [23]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-153 AND CYS-291.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [24]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-139.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J.,
RA   Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C.,
RA   Graubert T.A., DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting
CC       of two type II and two type I transmembrane serine/threonine
CC       kinases. Type II receptors phosphorylate and activate type I
CC       receptors which autophosphorylate, then bind and activate SMAD
CC       transcriptional regulators. Receptor for TGF-beta.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR: Magnesium or manganese (By similarity).
CC   -!- SUBUNIT: Interacts with CD109 and RBPMS. The unphosphorylated
CC       protein interacts with FKBP1A and is stabilized the inactive
CC       conformation. Phosphorylation of the GS region abrogates FKBP1A
CC       binding. Interacts with SMAD2 when phosphorylated on several
CC       residues in the GS region. Interacts with TRAF6.
CC   -!- INTERACTION:
CC       Q9Y3F4:STRAP; NbExp=1; IntAct=EBI-1027557, EBI-727414;
CC       P63104:YWHAZ; NbExp=2; IntAct=EBI-1027557, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Found in all tissues examined, most abundant
CC       in placenta and least abundant in brain and heart.
CC   -!- PTM: Phosphorylated at basal levels in the absence of ligand
CC       binding. Activated by multiple phosphorylation, mainly in the GS
CC       region.
CC   -!- DISEASE: Defects in TGFBR1 are the cause of Loeys-Dietz syndrome
CC       type 1A (LDS1A) [MIM:609192]; also known as Furlong syndrome or
CC       Loeys-Dietz aortic aneurysm syndrome (LDAS). LDS1 is an aortic
CC       aneurysm syndrome with widespread systemic involvement. The
CC       disorder is characterized by arterial tortuosity and aneurysms,
CC       craniosynostosis, hypertelorism, and bifid uvula or cleft palate.
CC       Other findings include exotropy, micrognathia and retrognathia,
CC       structural brain abnormalities, intellectual deficit, congenital
CC       heart disease, translucent skin, joint hyperlaxity and aneurysm
CC       with dissection throughout the arterial tree.
CC   -!- DISEASE: Defects in TGFBR1 are the cause of Loeys-Dietz syndrome
CC       type 2A (LDS2A) [MIM:608967]. LDS2 is an aortic aneurysm syndrome
CC       with widespread systemic involvement. Physical findings include
CC       prominent joint laxity, easy bruising, wide and atrophic scars,
CC       velvety and translucent skin with easily visible veins,
CC       spontaneous rupture of the spleen or bowel, diffuse arterial
CC       aneurysms and dissections, and catastrophic complications of
CC       pregnancy, including rupture of the gravid uterus and the
CC       arteries, either during pregnancy or in the immediate postpartum
CC       period. LDS2 is characterized by the absence of craniofacial
CC       abnormalities with the exception of bifid uvula that can be
CC       present in some patients.
CC   -!- DISEASE: Defects in TGFBR1 are the cause of aortic aneurysm
CC       familial thoracic type 5 (AAT5) [MIM:608967]. Aneurysms and
CC       dissections of the aorta usually result from degenerative changes
CC       in the aortic wall. Thoracic aortic aneurysms and dissections are
CC       primarily associated with a characteristic histologic appearance
CC       known as 'medial necrosis' in which there is degeneration and
CC       fragmentation of elastic fibers, loss of smooth muscle cells, and
CC       an accumulation of basophilic ground substance.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily.
CC   -!- SIMILARITY: Contains 1 GS domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/TGFBR1";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tgfbr1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L11695; AAA16073.1; -; mRNA.
DR   EMBL; AF054598; AAC08998.1; -; Genomic_DNA.
DR   EMBL; AF054590; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054591; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054592; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054593; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054594; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054595; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054596; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054597; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF035670; AAD02042.1; -; Genomic_DNA.
DR   EMBL; AF035662; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035663; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035664; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035665; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035666; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035667; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035668; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035669; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AY497473; AAR32097.1; -; Genomic_DNA.
DR   IPI; IPI00005733; -.
DR   PIR; A49432; A49432.
DR   RefSeq; NP_004603.1; -.
DR   UniGene; Hs.494622; -.
DR   PDB; 1B6C; X-ray; 2.60 A; B/D/F/H=162-503.
DR   PDB; 1IAS; X-ray; 2.90 A; A/B/C/D/E=162-503.
DR   PDB; 1PY5; X-ray; 2.30 A; A=175-500.
DR   PDB; 1RW8; X-ray; 2.40 A; A=200-500.
DR   PDB; 1TBI; Model; -; A=34-114.
DR   PDB; 1VJY; X-ray; 2.00 A; A=201-503.
DR   PDB; 2PJY; X-ray; 3.00 A; C=33-111.
DR   PDB; 2WOT; X-ray; 1.85 A; A=200-503.
DR   PDB; 2WOU; X-ray; 2.30 A; A=200-503.
DR   PDB; 3FAA; X-ray; 3.35 A; A/B/C/D/E=162-503.
DR   PDB; 3GXL; X-ray; 1.80 A; A=201-503.
DR   PDB; 3HMM; X-ray; 1.70 A; A=201-503.
DR   PDB; 3KCF; X-ray; 2.80 A; A/B/C/D/E=162-503.
DR   PDB; 3KFD; X-ray; 3.00 A; I/J/K/L=31-115.
DR   PDBsum; 1B6C; -.
DR   PDBsum; 1IAS; -.
DR   PDBsum; 1PY5; -.
DR   PDBsum; 1RW8; -.
DR   PDBsum; 1TBI; -.
DR   PDBsum; 1VJY; -.
DR   PDBsum; 2PJY; -.
DR   PDBsum; 2WOT; -.
DR   PDBsum; 2WOU; -.
DR   PDBsum; 3FAA; -.
DR   PDBsum; 3GXL; -.
DR   PDBsum; 3HMM; -.
DR   PDBsum; 3KCF; -.
DR   PDBsum; 3KFD; -.
DR   ProteinModelPortal; P36897; -.
DR   DIP; DIP-5935N; -.
DR   IntAct; P36897; 10.
DR   MINT; MINT-152959; -.
DR   STRING; P36897; -.
DR   PhosphoSite; P36897; -.
DR   PRIDE; P36897; -.
DR   Ensembl; ENST00000374994; ENSP00000364133; ENSG00000106799.
DR   GeneID; 7046; -.
DR   UCSC; uc004azc.1; human.
DR   CTD; 7046; -.
DR   GeneCards; GC09P101867; -.
DR   H-InvDB; HIX0008228; -.
DR   HGNC; HGNC:11772; TGFBR1.
DR   HPA; CAB002441; -.
DR   HPA; CAB031481; -.
DR   MIM; 190181; gene.
DR   MIM; 608967; phenotype.
DR   MIM; 609192; phenotype.
DR   Orphanet; 60030; Aortic aneurysm syndrome, Loeys-Dietz type.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm.
DR   Orphanet; 97295; Furlong syndrome.
DR   PharmGKB; PA36485; -.
DR   eggNOG; prNOG07264; -.
DR   HOGENOM; HBG314718; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; P36897; -.
DR   OMA; KIELPTT; -.
DR   OrthoDB; EOG9GTP07; -.
DR   PhylomeDB; P36897; -.
DR   BRENDA; 2.7.10.2; 247.
DR   BRENDA; 2.7.11.30; 247.
DR   Pathway_Interaction_DB; glypican_1pathway; Glypican 1 network.
DR   Pathway_Interaction_DB; tgfbrpathway; TGF-beta receptor signaling.
DR   Reactome; REACT_6844; Signaling by TGF beta.
DR   NextBio; 27533; -.
DR   ArrayExpress; P36897; -.
DR   Bgee; P36897; -.
DR   CleanEx; HS_TGFBR1; -.
DR   Genevestigator; P36897; -.
DR   GermOnline; ENSG00000106799; Homo sapiens.
DR   GO; GO:0070022; C:transforming growth factor beta receptor co...; IC:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IDA:BHF-UCL.
DR   GO; GO:0005025; F:transforming growth factor beta receptor ac...; IDA:BHF-UCL.
DR   GO; GO:0005114; F:type II transforming growth factor beta rec...; IDA:BHF-UCL.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:BHF-UCL.
DR   GO; GO:0009952; P:anterior/posterior pattern formation; ISS:BHF-UCL.
DR   GO; GO:0048844; P:artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:BHF-UCL.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0008354; P:germ cell migration; ISS:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:BHF-UCL.
DR   GO; GO:0001822; P:kidney development; ISS:BHF-UCL.
DR   GO; GO:0048663; P:neuron fate commitment; ISS:BHF-UCL.
DR   GO; GO:0060021; P:palate development; ISS:BHF-UCL.
DR   GO; GO:0060017; P:parathyroid gland development; ISS:BHF-UCL.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphoryla...; IDA:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0060037; P:pharyngeal system development; ISS:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:HGNC.
DR   GO; GO:0051272; P:positive regulation of cellular component m...; IMP:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted S...; IDA:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B sig...; IDA:BHF-UCL.
DR   GO; GO:0060391; P:positive regulation of SMAD protein nuclear...; IDA:BHF-UCL.
DR   GO; GO:0045885; P:positive regulation of survival gene produc...; IMP:BHF-UCL.
DR   GO; GO:0045941; P:positive regulation of transcription; IDA:BHF-UCL.
DR   GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL.
DR   GO; GO:0048538; P:thymus development; ISS:BHF-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor si...; IDA:BHF-UCL.
DR   InterPro; IPR000472; Activin_rcpt.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR003605; TGF_beta_rcpt_GS.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   SMART; SM00467; GS; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Aortic aneurysm; ATP-binding; Complete proteome;
KW   Craniosynostosis; Disease mutation; Disulfide bond; Glycoprotein;
KW   Kinase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Serine/threonine-protein kinase; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     24       Potential.
FT   CHAIN        25    503       TGF-beta receptor type-1.
FT                                /FTId=PRO_0000024423.
FT   TOPO_DOM     25    125       Extracellular (Potential).
FT   TRANSMEM    126    147       Helical; (Potential).
FT   TOPO_DOM    148    503       Cytoplasmic (Potential).
FT   DOMAIN      175    204       GS.
FT   DOMAIN      205    495       Protein kinase.
FT   NP_BIND     211    219       ATP (By similarity).
FT   ACT_SITE    333    333       Proton acceptor (By similarity).
FT   BINDING     232    232       ATP (By similarity).
FT   MOD_RES     165    165       Phosphoserine.
FT   MOD_RES     185    185       Phosphothreonine.
FT   MOD_RES     186    186       Phosphothreonine.
FT   MOD_RES     187    187       Phosphoserine.
FT   MOD_RES     189    189       Phosphoserine.
FT   MOD_RES     191    191       Phosphoserine.
FT   CARBOHYD     45     45       N-linked (GlcNAc...) (Potential).
FT   DISULFID     36     54
FT   DISULFID     38     41
FT   DISULFID     48     71
FT   DISULFID     86    100
FT   DISULFID    101    106
FT   VARIANT      24     26       Missing (in allele TGFBR1*6A; could be a
FT                                tumor susceptibility allele).
FT                                /FTId=VAR_022342.
FT   VARIANT      26     26       A -> AA (in allele TGFBR1*10A; rare
FT                                polymorphism).
FT                                /FTId=VAR_022343.
FT   VARIANT     139    139       I -> V.
FT                                /FTId=VAR_054160.
FT   VARIANT     153    153       V -> I (in dbSNP:rs56014374).
FT                                /FTId=VAR_041412.
FT   VARIANT     200    200       T -> I (in LDS1A).
FT                                /FTId=VAR_022344.
FT   VARIANT     232    232       K -> E (in LDS2A).
FT                                /FTId=VAR_029481.
FT   VARIANT     241    241       S -> L (in LDS1A).
FT                                /FTId=VAR_029482.
FT   VARIANT     267    267       N -> H (in a patient with Marfan
FT                                syndrome).
FT                                /FTId=VAR_029483.
FT   VARIANT     291    291       Y -> C (in dbSNP:rs35974499).
FT                                /FTId=VAR_041413.
FT   VARIANT     318    318       M -> R (in LDS1A).
FT                                /FTId=VAR_022345.
FT   VARIANT     400    400       D -> G (in LDS1A).
FT                                /FTId=VAR_022346.
FT   VARIANT     487    487       R -> P (in LDS1A and LDS2A).
FT                                /FTId=VAR_022347.
FT   VARIANT     487    487       R -> Q (in LDS2A and AAT5).
FT                                /FTId=VAR_029484.
FT   VARIANT     487    487       R -> W (in LDS2A).
FT                                /FTId=VAR_029485.
FT   MUTAGEN     185    186       TT->VV: Loss of phosphorylation on
FT                                threonine residues. Loss of threonine
FT                                phosphorylation, reduced phosphorylation
FT                                on serine residues and loss of response
FT                                to TGF-beta; when associated with A-187;
FT                                A-189 and A-191.
FT   MUTAGEN     187    187       S->A: Loss of threonine phosphorylation,
FT                                reduced phosphorylation on serine
FT                                residues and loss of response to TGF-
FT                                beta; when associated with 185-VV-186; A-
FT                                189 and A-191.
FT   MUTAGEN     189    189       S->A: Loss of threonine phosphorylation,
FT                                reduced phosphorylation on serine
FT                                residues and loss of response to TGF-
FT                                beta; when associated with 185-VV-186; A-
FT                                187 and A-191.
FT   MUTAGEN     191    191       S->A: Loss of threonine phosphorylation,
FT                                reduced phosphorylation on serine
FT                                residues and loss of response to TGF-
FT                                beta; when associated with 185-VV-186; A-
FT                                187 and A-189.
FT   MUTAGEN     200    200       T->D: Loss of response to TGF-beta.
FT   MUTAGEN     200    200       T->V: Loss of phosphorylation. Loss of
FT                                response to TGF-beta.
FT   MUTAGEN     204    204       T->D: Constitutive activation.
FT   MUTAGEN     204    204       T->V: Reduced phosphorylation. Reduced
FT                                response to TGF-beta.
FT   HELIX       177    183
FT   STRAND      191    193
FT   HELIX       195    199
FT   HELIX       202    204
FT   STRAND      206    212
FT   STRAND      215    217
FT   STRAND      219    224
FT   STRAND      227    234
FT   HELIX       239    251
FT   STRAND      262    267
FT   STRAND      271    273
FT   STRAND      276    280
FT   HELIX       288    294
FT   HELIX       299    317
FT   STRAND      328    330
FT   HELIX       336    338
FT   STRAND      339    341
FT   STRAND      347    349
FT   STRAND      356    359
FT   TURN        360    363
FT   STRAND      364    366
FT   HELIX       376    378
FT   HELIX       381    384
FT   HELIX       393    413
FT   TURN        427    431
FT   HELIX       438    445
FT   HELIX       456    459
FT   HELIX       462    472
FT   HELIX       479    481
FT   HELIX       485    499
SQ   SEQUENCE   503 AA;  55960 MW;  179F11404725DDCB CRC64;
     MEAAVAAPRP RLLLLVLAAA AAAAAALLPG ATALQCFCHL CTKDNFTCVT DGLCFVSVTE
     TTDKVIHNSM CIAEIDLIPR DRPFVCAPSS KTGSVTTTYC CNQDHCNKIE LPTTVKSSPG
     LGPVELAAVI AGPVCFVCIS LMLMVYICHN RTVIHHRVPN EEDPSLDRPF ISEGTTLKDL
     IYDMTTSGSG SGLPLLVQRT IARTIVLQES IGKGRFGEVW RGKWRGEEVA VKIFSSREER
     SWFREAEIYQ TVMLRHENIL GFIAADNKDN GTWTQLWLVS DYHEHGSLFD YLNRYTVTVE
     GMIKLALSTA SGLAHLHMEI VGTQGKPAIA HRDLKSKNIL VKKNGTCCIA DLGLAVRHDS
     ATDTIDIAPN HRVGTKRYMA PEVLDDSINM KHFESFKRAD IYAMGLVFWE IARRCSIGGI
     HEDYQLPYYD LVPSDPSVEE MRKVVCEQKL RPNIPNRWQS CEALRVMAKI MRECWYANGA
     ARLTALRIKK TLSQLSQQEG IKM
//
